Re:This old drug was free. Now it’s $109,500 a year
by otterley on Tuesday December 19, 2017 @12:27AM
(#15957990)
What “development” are you referring to, exactly? The alternate indications in many cases are already well known (as they were in the referenced article).
[ Parent
| on HN ]
Re:This old drug was free. Now it’s $109,500 a year
by notlob on Tuesday December 19, 2017 @06:18AM
(#15959360)
The clinical studies needed to support receiving approval to market the old drug for a new indication, as well as whatever lifecycle management and post-marketing surveillance activities (Phase IV) that are required. The alternate indications may be well-known but marketing for an off label indication is not permitted (as in, they actually jail CEOs and executives for that).